vs
Side-by-side financial comparison of Aligos Therapeutics, Inc. (ALGS) and Netcapital Inc. (NCPL). Click either name above to swap in a different company.
Aligos Therapeutics, Inc. is the larger business by last-quarter revenue ($169.0K vs $94.3K, roughly 1.8× Netcapital Inc.). On growth, Netcapital Inc. posted the faster year-over-year revenue change (-38.2% vs -72.1%). Over the past eight quarters, Netcapital Inc.'s revenue compounded faster (-47.9% CAGR vs -50.7%).
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
Netcapital Inc. runs a U.S.-focused digital private capital markets platform that connects growth-seeking early startups, small and medium private businesses with accredited and non-accredited individual investors, providing fundraising support for issuers and accessible alternative investment options for platform users.
ALGS vs NCPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $169.0K | $94.3K |
| Net Profit | — | $-1.8M |
| Gross Margin | — | 98.1% |
| Operating Margin | — | -2304.6% |
| Net Margin | — | -1921.5% |
| Revenue YoY | -72.1% | -38.2% |
| Net Profit YoY | 75.8% | 39.7% |
| EPS (diluted) | — | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $94.3K | ||
| Q4 25 | $169.0K | $51.1K | ||
| Q3 25 | $741.0K | $190.1K | ||
| Q2 25 | $965.0K | $404.0K | ||
| Q1 25 | $311.0K | $152.7K | ||
| Q4 24 | $606.0K | $170.5K | ||
| Q3 24 | $1.3M | $142.2K | ||
| Q2 24 | $1.1M | $347.2K |
| Q1 26 | — | $-1.8M | ||
| Q4 25 | — | $-2.1M | ||
| Q3 25 | $-31.5M | $-3.6M | ||
| Q2 25 | $-15.9M | $-20.5M | ||
| Q1 25 | $43.1M | $-3.0M | ||
| Q4 24 | $-82.2M | $-2.2M | ||
| Q3 24 | $-19.3M | $-2.5M | ||
| Q2 24 | $5.1M | — |
| Q1 26 | — | 98.1% | ||
| Q4 25 | — | 96.3% | ||
| Q3 25 | — | 96.1% | ||
| Q2 25 | — | 99.2% | ||
| Q1 25 | — | 95.3% | ||
| Q4 24 | — | 88.4% | ||
| Q3 24 | — | 92.8% | ||
| Q2 24 | — | 96.8% |
| Q1 26 | — | -2304.6% | ||
| Q4 25 | — | -4149.6% | ||
| Q3 25 | -3827.4% | -1728.8% | ||
| Q2 25 | -1924.0% | -476.0% | ||
| Q1 25 | -6187.5% | -1105.4% | ||
| Q4 24 | -3393.2% | -1291.5% | ||
| Q3 24 | -1610.5% | -1763.5% | ||
| Q2 24 | -2489.5% | — |
| Q1 26 | — | -1921.5% | ||
| Q4 25 | — | -4169.3% | ||
| Q3 25 | -4256.0% | -1916.3% | ||
| Q2 25 | -1643.8% | -5085.6% | ||
| Q1 25 | 13854.7% | -1969.1% | ||
| Q4 24 | -13556.1% | -1302.1% | ||
| Q3 24 | -1540.7% | -1776.9% | ||
| Q2 24 | 477.0% | — |
| Q1 26 | — | $-0.32 | ||
| Q4 25 | — | $-0.44 | ||
| Q3 25 | $-3.04 | $-1.27 | ||
| Q2 25 | $-1.53 | $-11.38 | ||
| Q1 25 | $-2.11 | $-1.57 | ||
| Q4 24 | $-13.10 | $-2.34 | ||
| Q3 24 | $-3.07 | $-5.10 | ||
| Q2 24 | $0.81 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $77.8M | — |
| Total DebtLower is stronger | — | $492.4K |
| Stockholders' EquityBook value | $53.5M | $21.6M |
| Total Assets | $88.5M | $26.1M |
| Debt / EquityLower = less leverage | — | 0.02× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $77.8M | — | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $122.9M | — | ||
| Q1 25 | $137.9M | — | ||
| Q4 24 | $56.9M | — | ||
| Q3 24 | $74.9M | — | ||
| Q2 24 | $94.5M | — |
| Q1 26 | — | $492.4K | ||
| Q4 25 | — | $495.8K | ||
| Q3 25 | — | $500.0K | ||
| Q2 25 | — | $500.0K | ||
| Q1 25 | — | $500.0K | ||
| Q4 24 | — | $500.0K | ||
| Q3 24 | — | $500.0K | ||
| Q2 24 | — | $500.0K |
| Q1 26 | — | $21.6M | ||
| Q4 25 | $53.5M | $21.4M | ||
| Q3 25 | $71.8M | $23.1M | ||
| Q2 25 | $101.9M | $14.9M | ||
| Q1 25 | $116.4M | $35.0M | ||
| Q4 24 | $-29.0M | $37.4M | ||
| Q3 24 | $50.1M | $37.5M | ||
| Q2 24 | $67.2M | $37.9M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | $88.5M | $25.4M | ||
| Q3 25 | $109.8M | $28.4M | ||
| Q2 25 | $134.7M | $20.9M | ||
| Q1 25 | $150.7M | $39.9M | ||
| Q4 24 | $70.1M | $41.9M | ||
| Q3 24 | $88.4M | $41.4M | ||
| Q2 24 | $108.8M | $41.6M |
| Q1 26 | — | 0.02× | ||
| Q4 25 | — | 0.02× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.03× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.01× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-82.5M | $-868.7K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-868.7K | ||
| Q4 25 | $-82.5M | $-2.6M | ||
| Q3 25 | $-24.3M | $-4.2M | ||
| Q2 25 | $-15.5M | $-5.3M | ||
| Q1 25 | $-20.9M | $-1.2M | ||
| Q4 24 | $-18.4M | $-1.5M | ||
| Q3 24 | $-20.1M | $-2.0M | ||
| Q2 24 | $-19.5M | $-4.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -3.85× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
